WO2026012091 - ESTROGEN RECEPTOR PROTEIN DEGRADATION-TARGETING CHIMERA COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/012091
Publication Date
15.01.2026
International Application No.
PCT/CN2025/102221
International Filing Date
19.06.2025
Title **
[English]
ESTROGEN RECEPTOR PROTEIN DEGRADATION-TARGETING CHIMERA COMPOUND AND USE THEREOF
[French]
COMPOSÉ CHIMÈRE CIBLANT LA DÉGRADATION DE PROTÉINE DU RÉCEPTEUR DES OESTROGÈNES ET SON UTILISATION
[Chinese]
一种雌激素受体蛋白降解靶向嵌合体化合物及其应用
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
XU, Fuming
CHEN, Wenmin
ZHOU, Guan
XUE, Wei
DING, Yongzheng
SHEN, Jie
YU, Weiwei
Priority Data
202410794445.5
19.06.2024
CN
202410867936.8
01.07.2024
CN
202411052955.1
02.08.2024
CN
202411125228.3
16.08.2024
CN
202411389793.0
08.10.2024
CN
202411538604.1
31.10.2024
CN
202411949325.4
27.12.2024
CN
202510302707.6
14.03.2025
CN
202510533416.8
26.04.2025
CN
202510726068.6
03.06.2025
CN
202411057231.6
02.08.2024
CN
202411119789.2
15.08.2024
CN
202411946736.8
27.12.2024
CN
202510348052.6
24.03.2025
CN
202510533415.3
26.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9126 | |
| EPO | Filing, Examination, Granting | 44710 | |
| Japan | Filing, Examination, Granting | 3275 | |
| South Korea | Filing, Examination, Granting | 4830 | |
| USA | Filing, Examination, Granting | 16740 |
Total:
78,681
Contact Us
Abstract[English]
Provided in the present invention are a new compound binding to an estrogen receptor protein, an estrogen receptor protein degradation-targeting chimera compound, and the medical use thereof. The compound provided in the present invention can be used as an estrogen receptor degrader for treating estrogen-dependent diseases.[French]
La présente invention concerne un nouveau composé se liant à une protéine du récepteur des oestrogènes, un composé chimère ciblant la dégradation de protéine du récepteur des oestrogènes, et leur utilisation médicale. Le composé selon la présente invention peut être utilisé en tant qu'agent de dégradation du récepteur des oestrogènes pour le traitement de maladies dépendantes des oestrogènes.[Chinese]
本发明提供了一种新型的结合雌激素受体蛋白的化合物，以及雌激素受体蛋白降解靶向嵌合体化合物，及其在医药中的应用。本发明提供的化合物能够作为雌激素受体降解剂用于雌激素依赖性疾病的治疗。